J 2017

Outcome of Alcohol Septal Ablation in Mildly Symptomatic Patients With Hypertrophic Obstructive Cardiomyopathy: A Long-Term Follow-Up Study Based on the Euro-Alcohol Septal Ablation Registry

VESELKA, Josef, Lothar FABER, Max LIEBREGTS, Robert COOPER, Jaroslav JANUSKA et. al.

Základní údaje

Originální název

Outcome of Alcohol Septal Ablation in Mildly Symptomatic Patients With Hypertrophic Obstructive Cardiomyopathy: A Long-Term Follow-Up Study Based on the Euro-Alcohol Septal Ablation Registry

Autoři

VESELKA, Josef (203 Česká republika), Lothar FABER (276 Německo), Max LIEBREGTS (528 Nizozemské království), Robert COOPER (826 Velká Británie a Severní Irsko), Jaroslav JANUSKA (203 Česká republika), Jan KREJČÍ (203 Česká republika, garant, domácí), Thomas BARTEL (40 Rakousko), Maciej DABROWSKI (616 Polsko), Peter Riis HANSEN (208 Dánsko), Vibeke Marie ALMAAS (578 Norsko), Hubert SEGGEWISS (276 Německo), Dieter HORSTKOTTE (276 Německo), Radka ADLOVA (203 Česká republika), Henning BUNDGAARD (208 Dánsko), Jurriën ten BERG (528 Nizozemské království), Rodney Hilton STABLES (826 Velká Británie a Severní Irsko) a Morten Kvistholm JENSEN (208 Dánsko)

Vydání

Journal of the American Heart Association, Hoboken, Wiley-Blackwell, 2017, 2047-9980

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 4.450

Kód RIV

RIV/00216224:14110/17:00097297

Organizační jednotka

Lékařská fakulta

UT WoS

000404098600056

Klíčová slova anglicky

ablation; hypertrophic cardiomyopathy; outcome

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 20. 3. 2018 13:59, Soňa Böhmová

Anotace

V originále

Background-The long-term efficacy and safety of alcohol septal ablation (ASA) in patients with highly symptomatic hypertrophic obstructive cardiomyopathy has been demonstrated. The aim of this study was to evaluate the long-term outcomes of mildly symptomatic patients with hypertrophic obstructive cardiomyopathy treated with ASA. Methods and Results-We retrospectively evaluated consecutive patients enrolled in the Euro-ASA registry (1427 patients) and identified 161 patients (53 +/- 13 years; 27% women) who were mildly symptomatic (New York Heart Association [NYHA] class II) pre-ASA. The median (interquartile range) follow-up was 4.8 (1.7-8.5) years. The clinical outcome was assessed and compared with the age-and sex-matched general population. The 30-day mortality after ASA was 0.6% and the annual all-cause mortality rate was 1.7%, which was similar to the age-and sex-matched general population (P=0.62). A total of 141 (88%) patients had resting left ventricular outflow tract gradient at the last clinical checkup <= 30 mm Hg. Obstruction was reduced from 63 +/- 32 to 15 +/- 19 mm Hg (P<0.01), and the mean NYHA class decreased from 2.0 +/- 0 to 1.3 +/- 0.1 (P<0.01); 69%, 29%, and 2% of patients were in NYHA class I, II, and III at the last clinical checkup, respectively. Conclusions-Mildly symptomatic hypertrophic obstructive cardiomyopathy patients treated with ASA had sustained symptomatic and hemodynamic relief with a low risk of developing severe heart failure. Their survival is comparable to the general population.